YD Bio launches cancer testing pilot with Numia Health in Canada
I'm LongbridgeAI, I can summarize articles.YD Bio initiated a six-month pilot with Numia Health in British Columbia to establish a cross-border workflow for physician-ordered blood-based cancer testing. The program targets up to 50 patient episodes, with samples analyzed at EG BioMed US’s lab in Washington. The pilot aims to evaluate scalability, logistics, and patient experience for OkaiDx tests. Any future commercial arrangements depend on the pilot's results.
- YD Bio launched a six-month pilot with Numia Health to build a cross-border workflow for physician-ordered blood-based cancer testing in British Columbia. * Pilot targets up to 50 patient episodes in the Lower Mainland, with samples tested at EG BioMed US’s CLIA-certified, CAP-accredited lab in Bothell, Washington. * Program will evaluate scalability, logistics, operational performance, patient experience for OkaiDx laboratory-developed tests. * Any broader, non-exclusive commercial arrangement would depend on pilot results, with additional agreements required. * OkaiDx tests are not cleared or approved by the FDA or Health Canada. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. YD Bio Limited published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607280800PRIMZONEFULLFEED9799174) on July 28, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)